FIRST AMENDMENT TO L-002-2016/0Kite Pharma, Inc. • May 9th, 2016 • Biological products, (no disgnostic substances)
This is the first amendment (“First Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of October 1, 2015 and having NIH Reference Number L-002-2016/0 (“Agreement”). This First Amendment, having NIH Reference Number L‑002-2016/1, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Kite Pharma, Inc., having an office at 2225 Colorado Avenue, Santa Monica, CA 90404 (the “Licensee”). This First Amendment includes, in addition to the amendment made below, a Signature Page.
SECOND AMENDMENT TO L-077-2015/0Second Amendment • May 9th, 2016 • Kite Pharma, Inc. • Biological products, (no disgnostic substances)
This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of December 31, 2014 and having NIH Reference Number L-077-2015/0 (“Agreement”). This Second Amendment, having NIH Reference Number L‑077‑2015/2, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Kite Pharma, Inc., having an office at 2225 Colorado Avenue, Santa Monica, CA 90404 (the “Licensee”). This Second Amendment includes, in addition to the amendments made below, a Signature Page.
SECOND AMENDMENT TO L-068-2013/0Second Amendment • May 9th, 2016 • Kite Pharma, Inc. • Biological products, (no disgnostic substances)
This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of April 11, 2013 and having NIH Reference Number L-068-2013/0 (“Agreement”). This Second Amendment, having NIH Reference Number L‑068‑2013/2, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Kite Pharma, Inc., having an office at 2225 Colorado Avenue, Santa Monica, CA 90404 (the “Licensee”). This Second Amendment includes, in addition to the amendment made below, a Signature Page.
SECOND AMENDMENT TO L-277-2014/0Second Amendment • May 9th, 2016 • Kite Pharma, Inc. • Biological products, (no disgnostic substances)
This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Kite Pharma, Inc. having an effective date of June 2, 2014 and having NIH Reference Number L-277-2014/0 (“Agreement”). This Second Amendment, having NIH Reference Number L‑277‑2014/2, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Kite Pharma, Inc., having an office at 2225 Colorado Avenue, Santa Monica, CA 90404 (the “Licensee”). This Second Amendment includes, in addition to the amendment made below, a Signature Page.
